1300 related articles for article (PubMed ID: 22955358)
1. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.
Barbara G; Zecchi L; Barbaro R; Cremon C; Bellacosa L; Marcellini M; De Giorgio R; Corinaldesi R; Stanghellini V
J Clin Gastroenterol; 2012 Oct; 46 Suppl():S52-5. PubMed ID: 22955358
[TBL] [Abstract][Full Text] [Related]
2. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.
Barbara G; Stanghellini V; Cremon C; De Giorgio R; Gargano L; Cogliandro R; Pallotti F; Corinaldesi R
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S214-7. PubMed ID: 18685517
[TBL] [Abstract][Full Text] [Related]
3. Treating irritable bowel syndrome with probiotics: the evidence.
Parkes GC; Sanderson JD; Whelan K
Proc Nutr Soc; 2010 May; 69(2):187-94. PubMed ID: 20236566
[TBL] [Abstract][Full Text] [Related]
4. Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome.
Barbara G; Stanghellini V; Cremon C; De Giorgio R; Fronzoni L; Serra M; Corinaldesi R
Dig Dis; 2009; 27 Suppl 1():115-21. PubMed ID: 20203507
[TBL] [Abstract][Full Text] [Related]
5. Mucosal barrier defects in irritable bowel syndrome. Who left the door open?
Barbara G
Am J Gastroenterol; 2006 Jun; 101(6):1295-8. PubMed ID: 16771952
[TBL] [Abstract][Full Text] [Related]
6. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG
J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
[TBL] [Abstract][Full Text] [Related]
7. Review article: probiotics and prebiotics in irritable bowel syndrome.
Spiller R
Aliment Pharmacol Ther; 2008 Aug; 28(4):385-96. PubMed ID: 18532993
[TBL] [Abstract][Full Text] [Related]
8. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome.
Ringel Y; Ringel-Kulka T
J Clin Gastroenterol; 2011 Nov; 45 Suppl():S145-8. PubMed ID: 21992954
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome.
Zeng J; Li YQ; Zuo XL; Zhen YB; Yang J; Liu CH
Aliment Pharmacol Ther; 2008 Oct; 28(8):994-1002. PubMed ID: 18671775
[TBL] [Abstract][Full Text] [Related]
10. Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy.
Camilleri M
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S123-5. PubMed ID: 18806702
[TBL] [Abstract][Full Text] [Related]
11. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.
Konturek PC; Brzozowski T; Konturek SJ
J Physiol Pharmacol; 2011 Dec; 62(6):591-9. PubMed ID: 22314561
[TBL] [Abstract][Full Text] [Related]
12. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome.
Camilleri M; Lasch K; Zhou W
Am J Physiol Gastrointest Liver Physiol; 2012 Oct; 303(7):G775-85. PubMed ID: 22837345
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment.
Parkes GC; Brostoff J; Whelan K; Sanderson JD
Am J Gastroenterol; 2008 Jun; 103(6):1557-67. PubMed ID: 18513268
[TBL] [Abstract][Full Text] [Related]
14. Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress.
Vicario M; Guilarte M; Alonso C; Yang P; Martínez C; Ramos L; Lobo B; González A; Guilà M; Pigrau M; Saperas E; Azpiroz F; Santos J
Brain Behav Immun; 2010 Oct; 24(7):1166-75. PubMed ID: 20600818
[TBL] [Abstract][Full Text] [Related]
15. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date.
Quigley EM; Flourie B
Neurogastroenterol Motil; 2007 Mar; 19(3):166-72. PubMed ID: 17300285
[TBL] [Abstract][Full Text] [Related]
16. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome.
Matricon J; Meleine M; Gelot A; Piche T; Dapoigny M; Muller E; Ardid D
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1009-31. PubMed ID: 23066886
[TBL] [Abstract][Full Text] [Related]
17. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship?
Braak B; Klooker TK; Wouters MM; Welting O; van der Loos CM; Stanisor OI; van Diest S; van den Wijngaard RM; Boeckxstaens GE
Am J Gastroenterol; 2012 May; 107(5):715-26. PubMed ID: 22488080
[TBL] [Abstract][Full Text] [Related]
18. A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats.
Agostini S; Goubern M; Tondereau V; Salvador-Cartier C; Bezirard V; Lévèque M; Keränen H; Theodorou V; Bourdu-Naturel S; Goupil-Feuillerat N; Legrain-Raspaud S; Eutamene H
Neurogastroenterol Motil; 2012 Apr; 24(4):376-e172. PubMed ID: 22272920
[TBL] [Abstract][Full Text] [Related]
19. Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation?
Piche T
Neurogastroenterol Motil; 2014 Mar; 26(3):296-302. PubMed ID: 24548256
[TBL] [Abstract][Full Text] [Related]
20. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
Drouault-Holowacz S; Bieuvelet S; Burckel A; Cazaubiel M; Dray X; Marteau P
Gastroenterol Clin Biol; 2008 Feb; 32(2):147-52. PubMed ID: 18387426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
